WAVE Life Sciences Stock Price, News & Analysis (NASDAQ:WVE)

$36.10 0.65 (1.83 %)
(As of 11/24/2017 04:18 AM ET)
Previous Close$35.45
Today's Range$35.10 - $36.40
52-Week Range$15.15 - $40.15
Volume120,253 shs
Average Volume103,063 shs
Market Capitalization$985.16 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.15

About WAVE Life Sciences (NASDAQ:WVE)

WAVE Life Sciences logoWAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388

Debt

Debt-to-Equity Ratio0.01%
Current Ratio11.50%
Quick Ratio11.50%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.49 million
Price / Sales673.30
Cash FlowN/A
Price / CashN/A
Book Value$5.97 per share
Price / Book6.05

Profitability

Trailing EPS($3.54)
Net Income$-55,400,000.00
Net Margins-3,338.68%
Return on Equity-59.52%
Return on Assets-48.48%

Miscellaneous

Employees96
Outstanding Shares27,790,000

Frequently Asked Questions for WAVE Life Sciences (NASDAQ:WVE)

What is WAVE Life Sciences' stock symbol?

WAVE Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How were WAVE Life Sciences' earnings last quarter?

WAVE Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.03. The firm earned $0.68 million during the quarter, compared to the consensus estimate of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. View WAVE Life Sciences' Earnings History.

When will WAVE Life Sciences make its next earnings announcement?

WAVE Life Sciences is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for WAVE Life Sciences.

Where is WAVE Life Sciences' stock going? Where will WAVE Life Sciences' stock price be in 2017?

5 brokerages have issued 1-year price objectives for WAVE Life Sciences' stock. Their forecasts range from $34.00 to $53.00. On average, they anticipate WAVE Life Sciences' share price to reach $41.60 in the next year. View Analyst Ratings for WAVE Life Sciences.

What are Wall Street analysts saying about WAVE Life Sciences stock?

Here are some recent quotes from research analysts about WAVE Life Sciences stock:

  • 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (10/12/2017)
  • 2. Jefferies Group LLC analysts commented, "During JEF Boston Bus Tour, we met with President/CEO Paul Bolno, M.D., Head of Neurology Franchise Michael Panzara, M.D., SVP of Drug Discovery Chandra Vargeese, Ph.D., & CFO Keith Regnante. With three stereopure oligo products advancing into clinic in 2017, we anticipate early clinical data on disease-modifying effect of its drug candidates for Huntington’s disease to be key catalysts, along with add’l potential partnerships in 2017. With 4 IND filings (goal of 2 IND filings per year) & 3 drug candidates in clinic by 2017, WVE poised to transition to a clincial-stage company from a platform company in next <12mo. Since its IPO in Oct. 2015, WVE has delivered on its timelines with progress in lead programs in Huntington’s disease (HD; WVE-120101, WVE-120102) & Duchenne Muscular Dystrophy (DMD) setting both programs to enter clinic in 2017. WVE notes its oligonucleotide facility will be GMP operational in ~2Q17, at which point it won't be constricted by CMOs. Solid execution in combination with positive read-through from BioMarin's (BMRN, Buy) drisapersen & Sarepta's (SRPT, Hold) Exondys 51 (eteplirsen) to WVE's potentially more potent & tolerable stereopure oligonucleotide for DMD has yielded ~100% appreciation for WVE shares in 2016."" (12/13/2016)

Who are some of WAVE Life Sciences' key competitors?

Who are WAVE Life Sciences' key executives?

WAVE Life Sciences' management team includes the folowing people:

  • Gregory L. Verdine Ph.D., Independent Chairman of the Board (Age 58)
  • Paul B. Bolno M.D., President, Chief Executive Officer, Director (Age 43)
  • Keith C. Regnante, Chief Financial Officer (Age 47)
  • Christopher Francis Ph.D., Senior Vice President, Corporate Development & Portfolio Management (Age 39)
  • Chandra Vargeese Ph.D., Senior Vice President, Head of Drug Discovery (Age 56)
  • Michael Panzara M.D., Franchise Lead, Neurology (Age 50)
  • Ken Takanashi, Director (Age 53)
  • Christian O. Henry, Additional Independent Director (Age 49)
  • Peter Kolchinsky Ph.D., Independent Director (Age 40)
  • Koji Miura, Independent Director (Age 68)

Who owns WAVE Life Sciences stock?

WAVE Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (2.31%), Point72 Asset Management L.P. (2.26%), JPMorgan Chase & Co. (0.43%), Schwab Charles Investment Management Inc. (0.20%), Mizuho Securities USA LLC (0.18%) and Bank of New York Mellon Corp (0.18%). Company insiders that own WAVE Life Sciences stock include Chandra Vargeese, Gregory L Verdine, Masaharu Tanaka, Michael A Panzara and Ra Capital Management, Llc. View Institutional Ownership Trends for WAVE Life Sciences.

Who sold WAVE Life Sciences stock? Who is selling WAVE Life Sciences stock?

WAVE Life Sciences' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have sold WAVE Life Sciences company stock in the last year include Chandra Vargeese, Masaharu Tanaka and Michael A Panzara. View Insider Buying and Selling for WAVE Life Sciences.

Who bought WAVE Life Sciences stock? Who is buying WAVE Life Sciences stock?

WAVE Life Sciences' stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., JPMorgan Chase & Co., Mizuho Securities USA LLC, Granite Point Capital Management L.P., Deschutes Portfolio Strategy LLC, Schwab Charles Investment Management Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for WAVE Life Sciences.

How do I buy WAVE Life Sciences stock?

Shares of WAVE Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is WAVE Life Sciences' stock price today?

One share of WAVE Life Sciences stock can currently be purchased for approximately $36.10.

How big of a company is WAVE Life Sciences?

WAVE Life Sciences has a market capitalization of $985.16 million and generates $1.49 million in revenue each year. The company earns $-55,400,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. WAVE Life Sciences employs 96 workers across the globe.

How can I contact WAVE Life Sciences?

WAVE Life Sciences' mailing address is 8 CROSS STREET, SINGAPORE U0, 048424. The company can be reached via phone at 65-6236-3388 or via email at [email protected]


MarketBeat Community Rating for WAVE Life Sciences (WVE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about WAVE Life Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for WAVE Life Sciences (NASDAQ:WVE)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.502.502.383.00
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.60$40.00$40.00$38.80
Price Target Upside: 68.08% upside75.05% upside113.33% upside82.16% upside

Consensus Price Target History for WAVE Life Sciences (NASDAQ:WVE)

Price Target History for WAVE Life Sciences (NASDAQ:WVE)

Analysts' Ratings History for WAVE Life Sciences (NASDAQ:WVE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Leerink SwannReiterated RatingOutperform$42.00 -> $53.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$34.00N/AView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingBuy$42.00 -> $40.00LowView Rating Details
6/9/2017JMP SecuritiesReiterated RatingOutperform$40.00LowView Rating Details
3/27/2017HC WainwrightReiterated RatingBuyHighView Rating Details
12/7/2015SunTrust Banks, Inc.Initiated CoverageBuy$26.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for WAVE Life Sciences (NASDAQ:WVE)

Earnings by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Earnings History by Quarter for WAVE Life Sciences (NASDAQ WVE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/9/2017Q3 2017($0.97)($0.94)$0.77 million$0.68 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.78)($0.92)$0.73 million$0.68 millionViewN/AView Earnings Details
5/10/20173/31/2017($0.77)($0.89)$0.80 million$0.68 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)($0.51)$0.42 millionViewN/AView Earnings Details
5/16/2016Q1($0.37)($0.36)ViewN/AView Earnings Details
3/30/2016Q4($0.28)($0.47)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for WAVE Life Sciences (NASDAQ:WVE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20181($1.11)($1.11)($1.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for WAVE Life Sciences (NASDAQ:WVE)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for WAVE Life Sciences (NASDAQ WVE)

Insider Ownership Percentage: 53.00%
Institutional Ownership Percentage: 69.47%
Insider Trades by Quarter for WAVE Life Sciences (NASDAQ:WVE)
Institutional Ownership by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Insider Trades by Quarter for WAVE Life Sciences (NASDAQ WVE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2017Chandra VargeeseInsiderSell1,500$35.00$52,500.00View SEC Filing  
11/14/2017Ra Capital Management, LlcDirectorBuy423,398$23.34$9,882,109.32View SEC Filing  
9/18/2017Masaharu TanakaDirectorSell20,747$24.21$502,284.87View SEC Filing  
7/12/2017Michael A PanzaraInsiderSell7,414$16.67$123,591.38View SEC Filing  
3/29/2017Masaharu TanakaDirectorSell433,825$24.91$10,806,580.75View SEC Filing  
6/15/2016Gregory L VerdineDirectorSell52,000$16.70$868,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for WAVE Life Sciences (NASDAQ WVE)

Source:
DateHeadline
Chandra Vargeese Sells 1,500 Shares of WAVE Life Sciences Ltd. (WVE) StockChandra Vargeese Sells 1,500 Shares of WAVE Life Sciences Ltd. (WVE) Stock
www.americanbankingnews.com - November 23 at 1:24 PM
 Analysts Expect WAVE Life Sciences Ltd. (WVE) Will Post Quarterly Sales of $640,000.00 Analysts Expect WAVE Life Sciences Ltd. (WVE) Will Post Quarterly Sales of $640,000.00
www.americanbankingnews.com - November 22 at 2:10 PM
Zacks: Analysts Anticipate WAVE Life Sciences Ltd. (WVE) to Post -$1.00 Earnings Per ShareZacks: Analysts Anticipate WAVE Life Sciences Ltd. (WVE) to Post -$1.00 Earnings Per Share
www.americanbankingnews.com - November 20 at 3:06 AM
WAVE Life Sciences Ltd. to Post FY2018 Earnings of ($4.52) Per Share, Leerink Swann Forecasts (WVE)WAVE Life Sciences Ltd. to Post FY2018 Earnings of ($4.52) Per Share, Leerink Swann Forecasts (WVE)
www.americanbankingnews.com - November 18 at 8:46 AM
Ra Capital Management, Llc Purchases 423,398 Shares of WAVE Life Sciences Ltd. (WVE) StockRa Capital Management, Llc Purchases 423,398 Shares of WAVE Life Sciences Ltd. (WVE) Stock
www.americanbankingnews.com - November 15 at 7:31 PM
WAVE Life Sciences Ltd. (WVE) Earns "Outperform" Rating from Leerink SwannWAVE Life Sciences Ltd. (WVE) Earns "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - November 15 at 11:42 AM
WAVE Life Sciences Ltd. (WVE) Given Average Recommendation of "Hold" by AnalystsWAVE Life Sciences Ltd. (WVE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 13 at 7:56 PM
WAVE Life Sciences Ltd. (WVE) Announces  Earnings ResultsWAVE Life Sciences Ltd. (WVE) Announces Earnings Results
www.americanbankingnews.com - November 10 at 2:34 PM
Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : November 8, 2017Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : November 8, 2017
finance.yahoo.com - November 9 at 10:13 AM
Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business UpdateWave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 10:13 AM
Wave Life Sciences reports 3Q lossWave Life Sciences reports 3Q loss
finance.yahoo.com - November 9 at 10:13 AM
WAVE Life Sciences Ltd. (WVE) Expected to Announce Quarterly Sales of $770,000.00WAVE Life Sciences Ltd. (WVE) Expected to Announce Quarterly Sales of $770,000.00
www.americanbankingnews.com - November 1 at 6:44 AM
Wave Life Sciences Ltd. – Value Analysis (NASDAQ:WVE) : October 30, 2017Wave Life Sciences Ltd. – Value Analysis (NASDAQ:WVE) : October 30, 2017
finance.yahoo.com - October 31 at 12:26 PM
Zacks: Brokerages Expect WAVE Life Sciences Ltd. (WVE) Will Announce Earnings of -$0.91 Per ShareZacks: Brokerages Expect WAVE Life Sciences Ltd. (WVE) Will Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - October 30 at 3:22 PM
WAVE Life Sciences Ltd. (WVE) Cut to "Sell" at BidaskClubWAVE Life Sciences Ltd. (WVE) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - October 28 at 7:02 AM
Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : October 27, 2017Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : October 27, 2017
finance.yahoo.com - October 27 at 4:58 PM
Short Interest Drops 15.8% For WVEShort Interest Drops 15.8% For WVE
www.thestreet.com - October 27 at 7:40 AM
BRIEF-Wave Life Sciences opens new 90,000 square foot manufacturing facilityBRIEF-Wave Life Sciences opens new 90,000 square foot manufacturing facility
www.reuters.com - October 27 at 7:40 AM
Wave Life Sciences Unveils New Manufacturing Facility in Lexington, MAWave Life Sciences Unveils New Manufacturing Facility in Lexington, MA
finance.yahoo.com - October 27 at 7:40 AM
ETFs with exposure to Wave Life Sciences Ltd. : October 23, 2017ETFs with exposure to Wave Life Sciences Ltd. : October 23, 2017
finance.yahoo.com - October 24 at 12:35 PM
WAVE Life Sciences Ltd. (WVE) PT Set at $34.00 by MizuhoWAVE Life Sciences Ltd. (WVE) PT Set at $34.00 by Mizuho
www.americanbankingnews.com - October 22 at 10:24 AM
WAVE Life Sciences Ltd. (WVE) Given Average Rating of "Buy" by AnalystsWAVE Life Sciences Ltd. (WVE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 19 at 6:50 PM
WAVE Life Sciences (WVE) Presents At Jefferies Gene Technology Investor Summit - SlideshowWAVE Life Sciences (WVE) Presents At Jefferies Gene Technology Investor Summit - Slideshow
seekingalpha.com - October 15 at 8:23 AM
 Brokerages Anticipate WAVE Life Sciences Ltd. (WVE) Will Post Quarterly Sales of $770,000.00 Brokerages Anticipate WAVE Life Sciences Ltd. (WVE) Will Post Quarterly Sales of $770,000.00
www.americanbankingnews.com - October 13 at 8:44 AM
WAVE Life Sciences Ltd. (WVE) Upgraded to Hold at Zacks Investment ResearchWAVE Life Sciences Ltd. (WVE) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 12 at 12:26 PM
Wave Life Sciences to Present at the Jefferies Gene Technology Investor SummitWave Life Sciences to Present at the Jefferies Gene Technology Investor Summit
finance.yahoo.com - October 12 at 10:19 AM
Short Interest in WAVE Life Sciences Ltd. (WVE) Grows By 27.9%Short Interest in WAVE Life Sciences Ltd. (WVE) Grows By 27.9%
www.americanbankingnews.com - September 30 at 3:50 AM
WAVE Life Sciences (WVE) vs. The Competition Head-To-Head ContrastWAVE Life Sciences (WVE) vs. The Competition Head-To-Head Contrast
www.americanbankingnews.com - September 27 at 6:22 AM
WAVE Life Sciences Ltd. (WVE) Receives Average Recommendation of "Hold" from AnalystsWAVE Life Sciences Ltd. (WVE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 24 at 6:42 PM
Insider Selling: WAVE Life Sciences Ltd. (WVE) Director Sells 20,747 Shares of StockInsider Selling: WAVE Life Sciences Ltd. (WVE) Director Sells 20,747 Shares of Stock
www.americanbankingnews.com - September 19 at 10:24 PM
WAVE Life Sciences (WVE) and RXi Pharmaceuticals Corporation (RXII) Critical ReviewWAVE Life Sciences (WVE) and RXi Pharmaceuticals Corporation (RXII) Critical Review
www.americanbankingnews.com - September 10 at 2:38 PM
ETFs with exposure to Wave Life Sciences Ltd. : September 1, 2017ETFs with exposure to Wave Life Sciences Ltd. : September 1, 2017
finance.yahoo.com - September 1 at 11:24 AM
Wave Life Sciences Ltd. breached its 50 day moving average in a Bullish Manner : WVE-US : August 28, 2017Wave Life Sciences Ltd. breached its 50 day moving average in a Bullish Manner : WVE-US : August 28, 2017
finance.yahoo.com - August 29 at 9:51 AM
Wave Life Sciences Ltd. :WVE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Wave Life Sciences Ltd. :WVE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:51 PM
Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of Stereochemical Purity in Oligonucleotide Drug DesignWave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of Stereochemical Purity in Oligonucleotide Drug Design
www.businesswire.com - August 22 at 8:02 AM
WAVE Life Sciences (WVE) & ANI Pharmaceuticals (BPAX) Head-To-Head ComparisonWAVE Life Sciences (WVE) & ANI Pharmaceuticals (BPAX) Head-To-Head Comparison
www.americanbankingnews.com - August 19 at 10:48 AM
Wave Life Sciences Ltd. – Value Analysis (NASDAQ:WVE) : August 17, 2017Wave Life Sciences Ltd. – Value Analysis (NASDAQ:WVE) : August 17, 2017
finance.yahoo.com - August 17 at 9:29 AM
-$0.90 EPS Expected for WAVE Life Sciences Ltd. (WVE) This Quarter-$0.90 EPS Expected for WAVE Life Sciences Ltd. (WVE) This Quarter
www.americanbankingnews.com - August 16 at 6:30 PM
WAVE Life Sciences Ltd. (WVE) Stock Rating Reaffirmed by Jefferies Group LLCWAVE Life Sciences Ltd. (WVE) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 10 at 9:34 PM
WAVE Life Sciences Ltd. (WVE) Releases  Earnings Results, Misses Estimates By $0.14 EPSWAVE Life Sciences Ltd. (WVE) Releases Earnings Results, Misses Estimates By $0.14 EPS
www.americanbankingnews.com - August 10 at 6:21 PM
Wave Life Sciences: Drug Candidates Finally In The ClinicWave Life Sciences: Drug Candidates Finally In The Clinic
seekingalpha.com - August 7 at 8:44 AM
WAVE Life Sciences Ltd. (WVE) to Release Quarterly Earnings on MondayWAVE Life Sciences Ltd. (WVE) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - August 7 at 7:08 AM
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Hold" by AnalystsWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - August 5 at 6:46 PM
Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : August 4, 2017Wave Life Sciences Ltd. breached its 50 day moving average in a Bearish Manner : WVE-US : August 4, 2017
finance.yahoo.com - August 4 at 10:06 AM
Financial Comparison: WAVE Life Sciences (NASDAQ:WVE) & Editas Medicine (EDIT)Financial Comparison: WAVE Life Sciences (NASDAQ:WVE) & Editas Medicine (EDIT)
www.americanbankingnews.com - August 2 at 8:22 PM
$730,000.00 in Sales Expected for WAVE Life Sciences Ltd. (WVE) This Quarter$730,000.00 in Sales Expected for WAVE Life Sciences Ltd. (WVE) This Quarter
www.americanbankingnews.com - July 31 at 9:34 AM
Wave Life Sciences Ltd. breached its 50 day moving average in a Bullish Manner : WVE-US : July 25, 2017Wave Life Sciences Ltd. breached its 50 day moving average in a Bullish Manner : WVE-US : July 25, 2017
finance.yahoo.com - July 25 at 8:39 AM
BRIEF-Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S DiseaseBRIEF-Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S Disease
www.reuters.com - July 18 at 1:31 AM
Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s DiseaseWave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
finance.yahoo.com - July 17 at 12:43 PM
Insider Selling: WAVE Life Sciences Ltd. (WVE) Insider Sells 7,414 Shares of StockInsider Selling: WAVE Life Sciences Ltd. (WVE) Insider Sells 7,414 Shares of Stock
www.americanbankingnews.com - July 13 at 8:16 PM

Social Media

Financials

Chart

WAVE Life Sciences (NASDAQ WVE) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.